Actimed Therapeutics

We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.

Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no globally approved pharmaceutical product for the treatment or prevention of cancer-related cachexia.

Our approach focuses on a class of agents that may have multiple effects on the fundamental biology of cachexia to reduce catabolism (weight loss), increase and maintain anabolism (weight gain, particularly muscle mass gain), decrease fatigue, and stimulate appetite.

Our lead product, S-pindolol benzoate (ACM-001.1) is a new salt of S-pindolol in clinical development for cancer-related cachexia. S-pindolol has demonstrated promising results in a Phase 2a, proof of concept trial and Phase 2b/3 clinical development programme is now planned. Our vision is to develop the first globally approved treatment for cancer cachexia and to develop a product portfolio to bring much needed innovation to the treatment of cachexia, amyotrophic lateral sclerosis and other muscle wasting conditions.

Our founders, Professor Andrew Coats and Professor Stefan Anker, are world-leading physicians in cachexia research, and the company is led by a management team and board with significant global experience in the development of new therapeutics across multiple indications.